These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 1175163)

  • 1. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin.
    Giuliani F; Casazza AM; Di Marco A; Savi G
    Cancer Treat Rep; 1981; 65(3-4):267-76. PubMed ID: 6263470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 4. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
    Holm B; Jensen PB; Sehested M
    Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA--anthracycline complexes. I. Toxicity in mice and chemotherapeutic activity against L1210 leukemia of daunorubicin--DNA and adriamycin--DNA.
    Deprez-de Campeneere D; Trouet A
    Eur J Cancer (1965); 1980 Aug; 16(8):981-6. PubMed ID: 7439227
    [No Abstract]   [Full Text] [Related]  

  • 6. Letter: DNA complexes of daunorubicin (NSC-8215) and adriamycin (NSC-123127).
    Trouet A; de Duve C
    Cancer Chemother Rep; 1975; 59(2 Pt 1):260. PubMed ID: 1149004
    [No Abstract]   [Full Text] [Related]  

  • 7. Adriamycin and cyclophosphamide in combination chemotherapy of L1210 leukemia.
    Avery TL; Roberts D
    Cancer Res; 1977 Mar; 37(3):678-83. PubMed ID: 837368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
    Deprez-de Campeneere D; Baurain R; Trouet A
    Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
    Herman EH; Ferrans VJ; Jordan W; Ardalan B
    Res Commun Chem Pathol Pharmacol; 1981 Jan; 31(1):85-97. PubMed ID: 6789416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICRF-187 in clinical oncology.
    Poster DS; Penta JS; Bruno S; Macdonald JS
    Cancer Clin Trials; 1981; 4(2):143-6. PubMed ID: 6788388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
    Marks TA; Venditti JM
    Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
    Schwartz HS
    Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
    [No Abstract]   [Full Text] [Related]  

  • 13. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits.
    Herman EH; Ferrans VJ
    Cancer Chemother Pharmacol; 1986; 16(2):102-6. PubMed ID: 3081268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.
    Israel M; Modest EJ; Frei E
    Cancer Res; 1975 May; 35(5):1365-8. PubMed ID: 1054622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the L isomer (+)-1,2-bis(3,5-dioxopiperazine-1-yl)propane on cell survival and cell cycle progression of cultured mammalian cells.
    Traganos F; Darzynkiewicz Z; Melamed MR
    Cancer Res; 1981 Nov; 41(11 Pt 1):4566-76. PubMed ID: 6171341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase.
    Holcenberg JS
    Cancer Treat Rep; 1979 Jun; 63(6):1109-14. PubMed ID: 466650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antileukemic activity of 4-demethoxydaunorubicin in mice.
    Casazza AM; Pratesi G; Giuliani F; Di Marco A
    Tumori; 1980 Oct; 66(5):549-64. PubMed ID: 6936969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
    Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
    Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
    Holm B; Sehested M; Jensen PB
    Clin Cancer Res; 1998 Jun; 4(6):1367-73. PubMed ID: 9626452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction by ICRF-187 of acute daunorubicin toxicity in Syrian golden hamsters.
    Herman EH; El-Hage AN; Ferrans VJ; Witiak DT
    Res Commun Chem Pathol Pharmacol; 1983 May; 40(2):217-31. PubMed ID: 6410471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.